The establishment of polypeptide PSMA‐targeted chimeric antigen receptor‐engineered natural killer cells for castration‐resistant prostate cancer and the induction of ferroptosis‐related cell death
暂无分享,去创建一个
Fan Wang | Fei-ya Yang | Fei Liu | Yuchun Gu | Xiying Dong | N. Xing | Liyuan Wu | Le Yin | Hui Shi | Qinxin Zhao | Dong Chen
[1] Yang Xu,et al. CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma , 2021, Cancer communications.
[2] Ruihua Xu,et al. Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 , 2021, Cancer communications.
[3] Yue Yang,et al. SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance , 2021, Cellular & molecular immunology.
[4] A. Rosato,et al. Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer , 2020, Cells.
[5] D. Campana,et al. NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.
[6] A. Chinnaiyan,et al. CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy , 2019, Nature.
[7] Qiong Zhang,et al. GSCALite: a web server for gene set cancer analysis , 2018, Bioinform..
[8] D. Kaufman,et al. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.
[9] G. Peng,et al. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer , 2018, Clinical Cancer Research.
[10] L. Gan,et al. Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric cancer , 2018, Oncogene.
[11] Ximing J. Yang,et al. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. , 2017, European urology.
[12] D. Bollino,et al. Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. , 2017, Translational research : the journal of laboratory and clinical medicine.
[13] R. Weichselbaum,et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression , 2017, Nature.
[14] E. Seifried,et al. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies , 2017, Cancer Immunology, Immunotherapy.
[15] B. Qin,et al. Discovery of PSMA-specific peptide ligands for targeted drug delivery. , 2016, International journal of pharmaceutics.
[16] M. Geyer,et al. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. , 2016, Blood.
[17] Christine E Brown,et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.
[18] D. Maloney,et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.
[19] S. Grupp,et al. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia , 2016, Current Treatment Options in Oncology.
[20] E. Crawford,et al. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. , 2015, The Journal of urology.
[21] M. Caligiuri,et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.
[22] Lewis L. Lanier,et al. NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.
[23] Biao Xu,et al. Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000–2009 , 2014, BMC Public Health.
[24] M. Caligiuri,et al. CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.
[25] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[26] S. Rosenberg,et al. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.
[27] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[28] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[29] M. Cheng,et al. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor , 2011, Cancer Gene Therapy.
[30] H. Mühl,et al. IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study , 2011, PloS one.
[31] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[32] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[33] H. Ljunggren,et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy , 2008, Cancer Immunology, Immunotherapy.
[34] H. Ljunggren,et al. Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.
[35] J. Isaacs,et al. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. , 2006, Cancer research.
[36] J. Quian,et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 2004, Histology and histopathology.
[37] M. Caligiuri,et al. Immunotherapeutic approaches for hematologic malignancies. , 2004, Hematology. American Society of Hematology. Education Program.
[38] I. Pastan,et al. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] A. Scott,et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. , 1997, Molecular immunology.